Use of an interleukin-10 antagonist to treat a B cell mediated a

Details Use of an interleukin-10 antagonist to treat a B cell mediated a Use of an interleukin-10 antagonist to treat a B cell mediated a

1995-06-07

1998-11-17

Draper, Garnette D.

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

424 851, 4241451, 4241581, 4241981, A61K 3819, A61K 3900

Patent

active

058372326

ABSTRACT:
A method is provided for toting a B cell mediated autoimmune disorder comprising administering an effective amount of an interleukin-10 antagonist.

REFERENCES:
Hsu, et al., "Differential Effects of IL-4 and IL-10 on I1-2-Induced IFN-.gamma. Synthesis and Lymphokine-Activated Killer Activity," International Immunology, vol. 4, No. 5, pp. 563-569, Jan. 27, 1992.
de Waal Malefyt, "Interleukin 10 (IL-10) Inhibits Cytokine Synthesis by Human Monocytes: An Autoregulatory Role of IL-10 Produced by Monocytes," J. Exp. Med., vol. 174, pp. 1209-1220, Nov., 1991.
Fiorentino, et al., "IL-10 Inhibits Cytokine Production by Activated Macrophages," The Journal of Immunology, vol. 147, No. 11, pp. 3815-3822, Dec. 1, 1991.
Scuderi, et al., "Raised Serum Levels of Tumour Necrosis Factor in Parasitic Infections," The Lancet, pp. 1364-1365, Dec. 13, 1986.
Westphal, O., "Bacterial Endotoxins," Int. Archs Allergy appl. Immun., vol. 49, pp. 1-43, 1975.
Kevin J. Tracey, et al., "Shock and Tissue Injury Induced by Recombinant Human Cachectin," Science, vol. 234, pp. 470-474, May 13, 1986.
Beutler, et al., "Cachectin and Tumour Necrosis Factor as Two Sides of the same Biological Coin," Nature, vol. 320, pp. 584-588, Apr. 17, 1986.
Tracey, et. al., "Anti-cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia," Nature, vol. 330, pp. 662-664, Dec. 17, 1987.
Waage, et al., "Association Between Tumour Necrosis Factor in Serum and Fatal Outcome in Patients with Meningococcal Disease," The Lancet, pp. 355-357, Feb. 14, 1987.
Girardin, et al., "Tumor Necrosis Factor and Interleukin-1 in the Serum of Children with Severe Infectious Purpura," Children with Severe Infectious Purpura, vol. 319, No. 7, pp. 397-400, Aug. 18, 1988.
Kern, et al., "Elevated Tumor Necrosis Factor Alpha and Interleukin-6 Serum Levels as Markers for Complicated Plasmodium falciparum Malaria," The American Journal of Medicine, vol. 87, pp. 139-143, Aug., 1989.
McIntosh, et al., "In Vivo Induction of IL-6 by Administration of Exogenous Cytokines and Dectection of De Novo Serum Levels of IL-6 in Tumor-Bearing Mice," The Journal of Immunology, vol. 143, pp. 162-167, Jul. 1, 1989.
Kishimoto, Tadamitsu, "The Biology of Interleukin-6," The Journal of The American Society of Hematology, vol. 74, No. 1, pp. 1-10, Jul., 1989.
Starnes, Jr., et al., "Anti-6 Monoclonal Antibodies Protect Against Lethal Escherichia coli, Infection and Lethal Tumor Necrosis Factor-.alpha. Challenge in Mice," The Journal of Immunology, vol. 145, No. 12, pp. 4185-4191, Dec. 15, 1990.
"Principles and Practice of Infectious Diseases," Second Edition, A Wiley Medical Publication, pp. 468-471.
Fiorentino, et al., "Two Types of Mouse T Helper Cell IV., Th2 Clones Secrete a Factor that Inhibits Cytokine Producion by Th1 Clones," J. Exp. Med., vol. 170, pp. 2081-2095, Dec., 1989.
Moore et al., "Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI," Science, vol. 248, pp. 1230-1234, Apr. 23, 1990.
Vieira et al., "Isolation and Expression of Human Cytokine Synthesis Inhibitory Factor cDNA Clones; Homology to Epstein-Barr Virus Open Reading Frame BCRFI," Proc. Natl. Acad. Sci. USA, Immunology, vol. 88, pp. 1172-1176, Feb., 1991.
Young, et al., "One Signal Requirement for Interferon-.gamma. Producton by Human Large Granular Lymphocytes," The Journal of Immunology, vol. 139, pp. 724-727, Aug. 1, 1987.
Kawakami, et al., "IL-4 Regulates IL-2 Induction of Lymphokine-Activity Killer Activity from Human Lymphocytes," The Journal of Immunology, vol. 142, No. 10, pp. 3452-3461, May 15, 1989.
de Waal Malefyt, et al., "Interleukin 10 (IL-10) and Viral IL-10 Strongly Reduced Antigen-specific Human T Cell Proliferation by Diminishing the Antigen-presenting Capacity of Monocytes via Downregulation of Class II Major Histocompatibility Complex Expression," J. Exp. Med., vol. 174, pp. 915-924, Oct., 1991.
te Velde, et al., "Interleukin-4 (IL-4) Inhibits Secretion of I1-1.beta., Tumor Necrosis Factor-.alpha. and IL-6 by Human Monocytes," Blood, vol. 76, No. 7, pp. 1392-1397, Oct. 1, 1990.
Aarden, et al., "Production of Hybridoma Growth Factor by Human Monocytes," Eur. J. Immunol., vol. 17, pp. 1411-1416, Jul. 11, 1987.
Lonnemann, et al., Differences in the Synthesis and Kinetics of Release of Interleukin 1.alpha., Interleukin 1.beta. and Tumor Necrosis Factor from Human Mononuclear Cells, Eur. J. Immunol., vol. 19, pp. 1531-1536, Apr. 1, 1989.
Fiorentino, et al., "IL-10 Acts on the Antigen-Presenting Cell to Inhibit Cytokine Production by Th1 Cells," The Journal of Immunology, vol. 146, No. 10, pp. 3444-3451, May 15, 1991.
Kappler, et al., "V.beta.-Specific Stimulation of Human T Cells by Staphylococcal Toxins," Science, vol. 244, pp. 811-813, May 19, 1989.
Simpson, Elizabeth, "Positive and Negative Selection of the T Cell Repertoire: Role of MHC and Other Ligands," Intern. Rev. Immunol., vol. 8, pp. 269-277, 1992.
Marrack et al., "The Toxicity of Staphylococcal Enterotoxin B in Mice is Mediated by T Cells," J. Exp. Med., vol. 171, pp. 455-464, Feb., 1990.
Miethke, et al., "T Cell-mediated Lethal Shock Triggered in Mice by the Superantigen Staphylococcal Enterotoxin B: Critical Role to Tumor Necrosis Factor," J. Exp. Med., vol. 175, pp. 91-98, Jan., 1992.
Beutler, et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," Science, vol. 229, pp. 869-871, Jul. 16, 1985.
Kappler, et al., "V.beta.-Specific Stimulation of Human T Cells by Staphylococcal Toxins," Science, vol. 244, pp. 811-813, May, 1989.
Alexander, et al., "A Recombinant Human Receptor Antagonist to Interleukin 1 Improves Survival after Lethal Endotoxemia in Mice," The Journal of Experimental Medicine, vol. 173, pp. 1029-1032, Apr., 1991.
Ishida, et al., "Continuous Anti-Interleukin 10 Antibody Administration Depletes Mice of Ly-1 B Cells by Not Conventional B Cells," The Journal of Experimental Medicine, vol. 175, pp. 1213-1220, May, 1992.
Herzenberg, et al., "The LY-1 B Cell Lineage," Immunological Reviews, No. 93, pp. 81-102.
Hayakawa, et al., "Normal, Autoimmune, and Malignant CD5+ B Cells: The LY-1 B Lineage?" Ann. Rev. Immunol., vol. 6, pp. 197-218, 1988.
Jacob, et al., "Tumour Necrosis Factor-.alpha. in Murine Autoimmune `Lupus` Nephritis," Nature, vol. 331, pp. 356-358, Jan., 1988.
Gordon, et al., "Chronic Therapy with Recombinant Tumor Necrosis Factor-.alpha. in Autoimmune NZB/NZW F.sub.1 Mice," Clinical Immunology and Immunopathology, vol. 52, pp. 421-434, 1989.
Theofilopoulos, et al., "Murine Models of Systemic Lupus Erythematosus," Advances in Immunology, vol. 37, pp. 269-390, 1985.
Rene de Waal Malefyt et al., "Interleukin-10," Current Opinion in Immunology, vol. 4, No. 3, pp. 314-320, Jun. 1992.
Maureen Howard et al., "Biological properties of interleukin-10," Immunology Today, vol. 13, No. 6, pp. 198-200, Jun. 1992.
Maureen Howard et al., "Biological Properties of Interleukin -10," Journal of Clinical Immunoolgy, vol. 12, No. 4, pp. 239-247, Jul. 1992.
Ian A. MacNeil et al., "IL-10, a Novel Growth Cofactor for Mature and Immature T Cells," Journal of Immunology, vol. 145, No. 12, pp. 4167-4173, Dec. 1990.
Tim R. Mossmann, et al., "Isolation of Monoclonal Antibodies Specific For IL-4, IL-5, IL-6, and a New Th2-Specific Cytokine (IL-10 ), Cytokine Synthesis Inhibitory Factor, By Using A Solid Phase Radioimmunoadsorbent Assay," The Journal of Immunology, 145(9):2938-2945, Nov. 1, 1990.

Affiliated with

Also associated with

Rating

Use of an interleukin-10 antagonist to treat a B cell mediated a does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of an interleukin-10 antagonist to treat a B cell mediated a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of an interleukin-10 antagonist to treat a B cell mediated a will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-881306